Zevra Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Zevra Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- ZVRA
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001434647
Board of directors
-
Alicia Secor · DirectorSince 2025
-
Alvin Shih · DirectorSince 2024
-
Corey Michael Watton · DirectorSince 2023
-
David S. Tierney · DirectorSince 2023
-
Douglas W. Calder · DirectorSince 2023
-
John B. Bode · DirectorSince 2023
-
Joseph Saluri · DirectorSince 2023
-
Matthew R. Plooster · DirectorSince 2023
-
Neil F. McFarlane · Director · President and CEOSince 2023
-
Richard W. Pascoe · Director · Chief Executive OfficerSince 2023
-
Tamara A. Seymour · DirectorSince 2023
-
Thomas Anderson · DirectorSince 2023
-
Wendy L. Dixon · DirectorSince 2023
Chief executives
Neil F. McFarlane
· President and CEO
Since October 2023
Richard W. Pascoe
· Chief Executive Officer
Until October 2023
· Former
Board connections
6 of this board's directors also sit on 8 other boards.
- via Tamara A. Seymour
- via Wendy L. Dixon
- via Wendy L. Dixon
- via Neil F. McFarlane
- via Douglas W. Calder
- via John B. Bode
- via Alvin Shih
- via Tamara A. Seymour
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $2,506,691
- 13 sales by 6 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 14, 2026 | Thompson Rahsaan Officer (Chief Legal & Compliance) | Open-market sale | −42,666 | $11.13 | $474,774 |
| Aug 10, 2026 | Corey Michael Watton Director | Option exercise | +12,300 | $4.97 | $61,131 |
| Aug 10, 2026 | Corey Michael Watton Director | Open-market sale | −12,300 | $11.25 | $138,377 |
| Jun 22, 2026 | Thompson Rahsaan Officer (Chief Legal & Compliance) | Open-market sale | −34,557 | $12.68 | $438,183 |
| Jun 21, 2026 | Thompson Rahsaan Officer (Chief Legal & Compliance) | Option exercise | +66,667 | — | — |
| May 11, 2026 | Thompson Rahsaan Officer (Chief Legal & Compliance) | Open-market sale | −1,794 | $11.30 | $20,272 |
| Mar 24, 2026 | John B. Bode Director | Option exercise | +39,200 | $4.97 | $194,824 |
| Mar 24, 2026 | John B. Bode Director | Option exercise | +39,200 | $4.89 | $191,688 |
| Feb 9, 2026 | Neil F. McFarlane Director, Officer (President and CEO) | Open-market sale | −14,625 | $8.56 | $125,190 |
| Feb 7, 2026 | Neil F. McFarlane Director, Officer (President and CEO) | Option exercise | +37,500 | — | — |
| Feb 3, 2026 | Sangiovanni Timothy J. Officer (SVP, Finance & Corp Controller) | Open-market sale | −3,000 | $9.18 | $27,540 |
| Feb 3, 2026 | Joshua Schafer Officer (CCO) | Open-market sale | −10,500 | $9.19 | $96,495 |
| Feb 2, 2026 | Neil F. McFarlane Director, Officer (President and CEO) | Open-market sale | −91,000 | $9.38 | $853,580 |
| Jan 31, 2026 | Neil F. McFarlane Director, Officer (President and CEO) | Option exercise | +233,334 | — | — |
| Jan 31, 2026 | Sangiovanni Timothy J. Officer (SVP, Finance & Corp Controller) | Option exercise | +11,666 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.